• Record: found
  • Abstract: found
  • Article: not found

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

The EMBO Journal

pharmacology, Valproic Acid, drug effects, Transcription, Genetic, genetics, Transcription Factors, Receptors, Glucocorticoid, Receptors, Cytoplasmic and Nuclear, Humans, Histone Deacetylase Inhibitors, Enzyme Inhibitors, Cricetinae, Cell Line, Transformed, Cell Differentiation, Animals

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Histone deacetylases (HDACs) play important roles in transcriptional regulation and pathogenesis of cancer. Thus, HDAC inhibitors are candidate drugs for differentiation therapy of cancer. Here, we show that the well-tolerated antiepileptic drug valproic acid is a powerful HDAC inhibitor. Valproic acid relieves HDAC-dependent transcriptional repression and causes hyperacetylation of histones in cultured cells and in vivo. Valproic acid inhibits HDAC activity in vitro, most probably by binding to the catalytic center of HDACs. Most importantly, valproic acid induces differentiation of carcinoma cells, transformed hematopoietic progenitor cells and leukemic blasts from acute myeloid leukemia patients. More over, tumor growth and metastasis formation are significantly reduced in animal experiments. Therefore, valproic acid might serve as an effective drug for cancer therapy.

      Related collections

      Author and article information



      Comment on this article